MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Harmony Biosciences Holdings Operating Income 2011-2026 | HRMY
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Harmony Biosciences Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 208 M | 191 M | 192 M | 120 M | 87.5 M | 17 M | -146 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 208 M | -146 M | 95.7 M |
Quarterly Operating Income Harmony Biosciences Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 65.5 M | 48.2 M | 56.2 M | - | 61.7 M | 21.4 M | 52 M | - | 64.5 M | 46.9 M | 40.4 M | - | 11.9 M | 33.1 M | 27.6 M | - | 21.1 M | 23.3 M | 14.5 M | - | 10.4 M | 7.31 M | -9.61 M | - | -29.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 65.5 M | -29.8 M | 29.8 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Altimmune
ALT
|
-94.5 M | $ 3.47 | 3.89 % | $ 306 M |  USA |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
-452 M | $ 219.83 | -0.92 % | $ 5 B |  Danmark |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-9.89 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-65.1 M | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Grifols, S.A.
GRFS
|
595 M | $ 7.69 | 1.39 % | $ 6.83 B |  Spain |
 |
Avenue Therapeutics
ATXI
|
-11.3 M | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-17.3 M | $ 0.6 | -2.83 % | $ 6.87 M |  Israel |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M | Israel |
 |
Cullinan Management
CGEM
|
-242 M | $ 13.01 | 2.12 % | $ 784 M | USA |
 |
BioDelivery Sciences International
BDSI
|
37.1 M | - | -4.8 % | $ 255 M | USA |
 |
Heron Therapeutics
HRTX
|
-2.54 M | $ 0.8 | 2.29 % | $ 133 M | USA |
 |
BeiGene, Ltd.
BGNE
|
447 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
-115 M | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
-121 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-130 M | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
-22.4 M | - | -74.18 % | $ 955 K | USA |
 |
Incyte Corporation
INCY
|
1.51 B | $ 91.13 | 0.38 % | $ 17.8 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
-56.2 M | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
-226 M | - | -7.23 % | $ 13 M | USA |
 |
Inovio Pharmaceuticals
INO
|
-144 M | $ 1.6 | 0.95 % | $ 35.5 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Denali Therapeutics
DNLI
|
-487 M | $ 21.15 | 4.86 % | $ 3.48 B | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Inventiva S.A.
IVA
|
-52.1 M | $ 6.07 | 5.02 % | $ 138 M | France |
 |
Arbutus Biopharma Corporation
ABUS
|
-78.1 M | $ 4.3 | 1.3 % | $ 714 M | Canada |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
AIkido Pharma
AIKI
|
-11.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
-12 M | - | -5.98 % | $ 34.1 M | USA |
 |
Decibel Therapeutics
DBTX
|
-64 M | - | - | $ 123 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-211 M | - | - | $ 2.18 B | USA |
 |
Cardiff Oncology
CRDF
|
-49 M | $ 1.8 | 0.08 % | $ 120 M | USA |